Monitor for study results by mid-2026, which could support expanded adoption of CyPath Lung in clinical settings and potentially lead to new commercialization pathways. This represents a strategic step in product development rather than an immediate financial catalyst.
Price Chart
Executive Summary
bioAffinity Technologies announced a new clinical study with Brooke Army Medical Center to validate the use of its CyPath Lung test on sputum samples obtained via tracheal and bronchial suctioning. The study aims to expand sample collection options for early lung cancer detection and could broaden the test's clinical utility.
Key Facts
- bioAffinity Technologies is conducting a validation study with Brooke Army Medical Center (BAMC) to assess the CyPath Lung test using sputum samples from tracheal and bronchial suctioning.
- The study will enroll 30-50 patients and is expected to conclude by mid-2026.
- CyPath Lung is a noninvasive test using flow cytometry and AI to detect lung cancer, with previously reported 92% sensitivity and 87% specificity.
- The current standard protocol uses home-collected sputum; this study explores clinical setting collection during bronchoscopy or suction procedures.
- Bronchoscopy is performed approximately 500,000 times annually in the U.S., representing a potential expansion opportunity for the test.
Financial Impact
No financial impact disclosed. The study is a clinical validation effort with no immediate revenue or cost implications reported.
Risk Factors
- Study may not demonstrate sufficient clinical utility or performance with suctioned samples.
- Regulatory or commercial adoption challenges could limit the impact even if the study is successful.
- Company is an emerging growth company with likely limited revenue and high reliance on successful product development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-007965 |
| Exhibit: ex99-1.htm | 0001493152-26-007965 |
| Document: 0001493152-26-007965-index-headers.html | 0001493152-26-007965 |
| Document: 0001493152-26-007965-index.html | 0001493152-26-007965 |
| Document: 0001493152-26-007965.txt | 0001493152-26-007965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 18d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 20d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 26d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 4w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers